Background：Dilpacimab formerly ABT-165, a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 DLL4 and VEGF pathways. Here, we present safety, pharmacokinetic PK, pharmacodynamic PD, and preliminary efficacy data from a phase I study trial registration ID: NCT01946074 of dilpacimab in patients with advanced solid tumors. Eligible patients ≥18 years received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels range, 1.25–7.5 mg/kg until progressive disease or unacceptable toxicity.
